Effect of statin on risk of gynecologic cancers: A meta-analysis of observational studies and randomized controlled trials

Gynecologic Oncology

Volumn 133, Issue 3, 2014, Pages 647-655

  Liu, Yanqiong ^a   Qin, Aiping ^a   Li, Taijie ^a   Qin, Xue ^a   Li, Shan ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Cervical cancer; Endometrial cancer; Gynecologic cancers; Ovarian cancer; Statin

Indexed keywords

ATORVASTATIN; CERIVASTATIN; COMPACTIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

CANCER LOCALIZATION; CANCER RISK; CONFIDENCE INTERVAL; ENDOMETRIUM CANCER; GYNECOLOGIC CANCER; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; UTERINE CERVIX CANCER; VULVA CANCER;

CERVICAL CANCER; ENDOMETRIAL CANCER; GYNECOLOGIC CANCERS; OVARIAN CANCER; STATIN;

ENDOMETRIAL NEOPLASMS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; OVARIAN NEOPLASMS; RISK; UTERINE CERVICAL NEOPLASMS; VULVAR NEOPLASMS;

EID: 84901655908     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.04.007     Document Type: Review

References (46)

1. K.A.H. Nicolaije, N.P.M. Ezendam, M.C. Vos, D. Boll, J.M.A. Pijnenborg, and R.F.P.M. Kruitwagen et al. Follow-up practice in endometrial cancer and the association with patient and hospital characteristics: a study from the population-based PROFILES registry Gynecol Oncol 129 2013 324 331
2. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J Clin 64 2014 9 29
3. Ovarian Cancer The Merck Manual for Health Care Professionals September 2013 [Table 7. http://www.merckmanuals.com/professional/gynecology-and- obstetrics/gynecologic-tumors/ovarian-cancer.html ]
4. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, and D.M. Parkin Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2010 2893 2917
5. H.L. Liu, S.L. Liang, S. Kumar, C.M. Weyman, W.D. Liu, and A.M. Zhou Statins induce apoptosis in ovarian cancer cells through activation of JNK and enhancement of Bim expression Cancer Chemother Pharmacol 63 2009 997 1005
6. A. Martirosyan, J.W. Clendening, C.A. Goard, and L.Z. Penn Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance BMC Cancer 10 2010 103
7. S. Kato, S. Smalley, A. Sadarangani, K. Chen-Lin, B. Oliva, and J. Branes et al. Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase J Cell Mol Med 14 2010 1180 1193
8. D.L. Ornstein, and C. Wong Statins inhibit the growth of human ovarian cancer and potentiate the antineoplastic effect of carboplatin J Soc Gynecol Investig 13 2006 168A 169A
9. M. Cuello, S. Kato, D. Diaz, and G. Owen Effects of statins in cancer Rev Med Chil 141 2013 227 236
10. W.W.L. Wong, J. Dimitroulakos, M.D. Minden, and L.Z. Penn HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis Leukemia 16 2002 508 519
11. M. Benn, A. Tybjaerg-Hansen, S. Stender, R. Frikke-Schmidt, and B.G. Nordestgaard Low-density lipoprotein cholesterol and the risk of cancer: a mendelian randomization study J Natl Cancer Inst 103 2011 508 519
12. M. Clearfield, J.R. Downs, S. Weis, E.J. Whitney, W. Kruyer, and D.R. Shapiro et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women J Womens Health Gend Based Med 10 2001 971 981
13. T.E. Strandberg, K. Pyorala, T.J. Cook, L. Wilhelmsen, O. Faergeman, and G. Thorgeirsson et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S) Lancet 364 2004 771 777
14. Heart Protection Study Collaborative G The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393] BMC Med 3 2005
15. H. Nakamura, K. Arakawa, H. Itakura, A. Kitabatake, Y. Goto, and T. Toyota et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial Lancet 368 2006 1155 1163
16. S. Friis, A.H. Poulsen, S.P. Johnsen, J.K. McLaughlin, J.P. Fryzek, and S.O. Dalton et al. Cancer risk among statin users: a population-based cohort study Int J Cancer 114 2005 643 647
17. G.D. Friedman, E.D. Flick, N. Udaltsova, J. Chan, C.P. Quesenberry Jr., and L.A. Habel Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361 859 recipients Pharmacoepidemiol Drug Saf 17 2008 27 36
18. O. Yu, D.M. Boudreau, D.S. Buist, and D.L. Miglioretti Statin use and female reproductive organ cancer risk in a large population-based setting Cancer Causes Control 20 2009 609 616
19. J. Haukka, R. Sankila, T. Klaukka, J. Lonnqvist, L. Niskanen, and A. Tanskanen et al. Incidence of cancer and statin usage - record linkage study Int J Cancer 126 2010 279 284
20. E.J. Jacobs, C.C. Newton, M.J. Thun, and S.M. Gapstur Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort Cancer Res 71 2011 1763 1771
21. L. Blais, A. Desgagne, and J. LeLorier 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study Arch Intern Med 160 2000 2363 2368
22. J.A. Kaye, and H. Jick Statin use and cancer risk in the General Practice Research Database Br J Cancer 90 2004 635 637
23. P.F. Coogan, L. Rosenberg, and B.L. Strom Statin use and the risk of 10 cancers Epidemiology 18 2007 213 219
24. O. Lavie, M. Pinchev, H.S. Rennert, Y. Segev, and G. Rennert The effect of statins on risk and survival of gynecological malignancies Gynecol Oncol 130 2013 615 619
25. H.W. Leung, A.L. Chan, D. Lo, J.H. Leung, and H.L. Chen Common cancer risk and statins: a population-based case-control study in a Chinese population Expert Opin Drug Saf 12 2013 19 27
26. J. Kuoppala, A. Lamminpaa, and E. Pukkala Statins and cancer: a systematic review and meta-analysis Eur J Cancer 44 2008 2122 2132
27. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, and P. Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement BMJ 339 2009 b2535
28. J.P. Higgins, D.G. Altman, P.C. Gotzsche, P. Juni, D. Moher, and A.D. Oxman et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials BMJ 343 2011 d5928
29. G.A. Wells, B. Shea, D. O'Connell, J. Peterson, V. Welch, and M. Losos et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2009 [ http://www.ohri.ca/programs/clinical- epidemiology/oxford.asp ]
30. S. Greenland Quantitative methods in the review of epidemiologic literature Epidemiol Rev 9 1987 1 30
31. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
32. J.P. Higgins, S.G. Thompson, J.J. Deeks, and D.G. Altman Measuring inconsistency in meta-analyses BMJ 327 2003 557 560
33. J.P. Higgins, and S.G. Thompson Quantifying heterogeneity in a meta-analysis Stat Med 21 2002 1539 1558
34. M. Egger, G. Davey Smith, M. Schneider, and C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 629 634
35. C.B. Begg, and M. Mazumdar Operating characteristics of a rank correlation test for publication bias Biometrics 50 1994 1088 1101
36. J. Copas, and J.Q. Shi Meta-analysis, funnel plots and sensitivity analysis Biostatistics 1 2000 247 262
37. D.M. Boudreau, O. Yu, and J. Johnson Statin use and cancer risk: a comprehensive review Expert Opin Drug Saf 9 2010 603 621
38. R.J. Deberardinis, N. Sayed, D. Ditsworth, and C.B. Thompson Brick by brick: metabolism and tumor cell growth Curr Opin Genet Dev 18 2008 54 61
39. P.P. Singh, and S. Singh Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis Ann Oncol 24 2013 1721 1730
40. X.L. Zhang, J. Geng, X.P. Zhang, B. Peng, J.P. Che, and Y. Yan et al. Statin use and risk of bladder cancer: a meta-analysis Cancer Causes Control 24 2013 769 776
41. S. Singh, P.P. Singh, A.G. Singh, M.H. Murad, and W. Sanchez Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis Gastroenterology 144 2013 323 332
42. K. Undela, V. Srikanth, and D. Bansal Statin use and risk of breast cancer: a meta-analysis of observational studies Breast Cancer Res Treat 135 2012 261 269
43. Y. Liu, W. Tang, J. Wang, L. Xie, T. Li, and Y. He et al. Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies Cancer Causes Control 25 2014 237 249
44. S.F. Nielsen, B.G. Nordestgaard, and S.E. Bojesen Statin use and reduced cancer-related mortality N Engl J Med 367 2012 1792 1802
45. R.G. Elmore, Y. Ioffe, D.R. Scoles, B.Y. Karlan, and A.J. Li Impact of statin therapy on survival in epithelial ovarian cancer Gynecol Oncol 111 2008 102 105
46. B.A. Hamelin, and J. Turgeon Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors Trends Pharmacol Sci 19 1998 26 37